Evidence map›Paper›PMID 31730496›Full record

ArticleOrphanet journal of rare diseases2019

Genetic and clinical characterization of 73 Pigmentary Mosaicism patients: revealing the genetic basis of clinical manifestations.

C Salas-Labadía, S Gómez-Carmona, R Cruz-Alcívar, D Martínez-Anaya, V Del Castillo-Ruiz, C Durán-McKinster, V Ulloa-Avilés, E Yokoyama-Rebollar, A Ruiz-Herrera, P Navarrete-Meneses and 9 more

Abstract read
In one paragraph

Article in Orphanet journal of rare diseases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Neurocutaneous syndromes in art and antiquities.American journal of medical genetics. Part C, Seminars in medical genetics · 2021
    Review
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

C Salas-LabadíaLaboratorio de Genética y Cáncer, Departamento de Genética Humana, Instituto Nacional de Pediatría, 04530, Ciudad de México, Mexico. consusa@hotmail.com.ORCID 0000-0002-3301-7357
S Gómez-CarmonaDepartamento de Genética Médica, Centro de Rehabilitación e Inclusión Infantil Teletón, Tuxtla Gutiérrez, Chiapas, Mexico.
R Cruz-AlcívarLaboratorio de Genética y Cáncer, Departamento de Genética Humana, Instituto Nacional de Pediatría, 04530, Ciudad de México, Mexico.
D Martínez-AnayaLaboratorio de Genética y Cáncer, Departamento de Genética Humana, Instituto Nacional de Pediatría, 04530, Ciudad de México, Mexico.
V Del Castillo-RuizDepartamento de Genética Humana, Instituto Nacional de Pediatría, Ciudad de México, Mexico.
C Durán-McKinsterDepartamento de Dermatología, Instituto Nacional de Pediatría, Ciudad de México, Mexico.
V Ulloa-AvilésLaboratorio de Genética y Cáncer, Departamento de Genética Humana, Instituto Nacional de Pediatría, 04530, Ciudad de México, Mexico.
E Yokoyama-RebollarDepartamento de Genética Humana, Instituto Nacional de Pediatría, Ciudad de México, Mexico.
A Ruiz-HerreraHospital de Especialidades Pediátrico de León, León, Guanajuato, Mexico.
P Navarrete-MenesesLaboratorio de Genética y Cáncer, Departamento de Genética Humana, Instituto Nacional de Pediatría, 04530, Ciudad de México, Mexico.
E Lieberman-HernándezDepartamento de Genética Humana, Instituto Nacional de Pediatría, Ciudad de México, Mexico.
A González-Del AngelLaboratorio de Biología Molecular, Departamento de Genética Humana, Instituto Nacional de Pediatría, Ciudad de México, Mexico.
D Cervantes-BarragánHospital Central Sur de Alta Especialidad, PEMEX, Ciudad de México, Mexico.
C Villarroel-CortésDepartamento de Genética Humana, Instituto Nacional de Pediatría, Ciudad de México, Mexico.
A Reyes-LeónLaboratorio de Genética y Cáncer, Departamento de Genética Humana, Instituto Nacional de Pediatría, 04530, Ciudad de México, Mexico.
D Suárez-PérezDepartamento de Genética Humana, Instituto Nacional de Pediatría, Ciudad de México, Mexico.
A Pedraza-MeléndezLaboratorio de Genética y Cáncer, Departamento de Genética Humana, Instituto Nacional de Pediatría, 04530, Ciudad de México, Mexico.
A González-OrsunaLaboratorio de Genética y Cáncer, Departamento de Genética Humana, Instituto Nacional de Pediatría, 04530, Ciudad de México, Mexico.
P Pérez-VeraLaboratorio de Genética y Cáncer, Departamento de Genética Humana, Instituto Nacional de Pediatría, 04530, Ciudad de México, Mexico. pperezvera@yahoo.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPigmentary mosaicism constitutes a heterogeneous group of skin pigmentation alterations associated with multisystem involvement. The aim of this study was to establish a complete cytogenetic and molecular characterization of PM patients, emphasizing on searching for possible low chromosomal mosaicism and on establishing an accurate genotype-phenotype correlation.

resultsA total of 73 patients were included (3 months to 18 years of age), 52% male and 48% female. Observed in 69 (95%) patients, the most frequent pattern of pigmentation was fine and whorled BL, which was associated with disseminated skin extent in 41 (59%) patients. Central nervous system (84%) alterations were the most frequent observed in the group of patients, followed by the musculoskeletal (53%) and ophthalmologic (27%) alterations. Considering the pattern of pigmentation, no significant differences in association with skin extent or extracutaneous manifestations were detected. Following a strict cytogenetic analysis strategy, screening metaphases from three different tissues (peripheral blood, hyperpigmented and hypopigmented skin) we found that 23/73 patients had chromosomal abnormalities classified as follows: 1) Mosaic with 2 or more different cell lines with structural alterations n = 19; 2) Polyploidy (mosaic) n = 1 and 3) Alterations in all cells in three different tissues n = 3. SNP array, array CGH and FISH were useful for the complete characterization of the chromosomal aberrations, for the detection of microdeletions in patients with normal karyotype but with strong clinical suspicious of chromosomal alteration, and for a better establishment of genotype-phenotype correlation. In 2 patients we found genes associated with some of the extracutaneous manifestations (SHH, MNX1, PPP2R2C).

conclusionsThis group of 73 patients finely described is the largest series of patients with pigmentary mosaicism reported worldwide. As we showed in this study, the followed analysis strategy allowed the detection of cytogenetic and molecular abnormalities, and made possible the establishment of genotype-phenotype associations in some patients. An important limitation of our study was the analysis of fibroblasts cultures instead of melanocytes and keratinocytes. In some cases the direct molecular DNA analysis of skin biopsy could be another choice.

Indexed as

AdolescentChildChild, PreschoolFemaleGenetic Association StudiesHumansHyperpigmentationHypopigmentationInfantKaryotypingKeratinocytesMaleMelanocytesSkin PigmentationCytogenetic and molecular characterizationGenotype-phenotype correlationPigmentary mosaicism

Identifiers

PMID31730496
PMCPMC6858688

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.